United States Drug Patent 7,179,815: Claim Scope, Patent Strength, Expiration, and Generic Entry Risk

US 7,179,815 is a broad method-of-treatment patent covering a chemically defined genus of small-molecule compounds, stereoisomers, salts, and, in one claim, prodrugs. Its asserted therapeutic scope includes reproductive, endocrine, oncologic, gynecologic, urologic, autoimmune, gastrointestinal, growth, and sleep indications.

The patent issued on February 20, 2007. The claims supplied are method claims rather than composition-of-matter claims. Their commercial value therefore depends on whether a marketed or pipeline compound falls within the claimed chemical genus and whether the relevant indication is practiced in the United States.

The chemical structure referenced in each claim is absent from the supplied text. That omission prevents a molecule-by-molecule determination for elagolix, relugolix, degarelix, ganirelix, leuprolide, or other GnRH-pathway products. The claim architecture, however, supports a detailed legal and competitive assessment.

What does US Patent 7,179,815 cover?

The patent covers administering a compound with a large Markush structure to treat specified conditions or prevent pregnancy. The claims encompass:

A central heteroatom-containing scaffold with A selected from oxygen, sulfur, or NR7.
A linker Q that may be a direct bond or a substituted, heteroatom-containing chain.
Multiple independently variable substituents, including alkyl, aryl, heteroaryl, heterocyclic, amino, amide, sulfonyl, ester, ether, thioether, and carbonyl groups.
Stereoisomers.
Pharmaceutically acceptable salts.
Prodrugs under claim 6.
Treatment and prevention methods rather than a standalone compound or composition.

The genus is materially broader than a single clinical candidate. It attempts to capture chemical diversity around a pharmacologically active core and to extend protection across multiple therapeutic applications.

Claim structure

Claim	Type	Subject matter
1	Independent method claim	Treatment of 11 listed conditions using the defined compound genus
2	Dependent	Benign prostatic hypertrophy or uterine myoma
3	Dependent	Prostate, uterine, or breast cancer; pituitary gonadotroph adenomas
4	Dependent	Endometriosis, polycystic ovarian disease, uterine fibroids, or precocious puberty
5	Independent method claim	Pregnancy prevention using the compound genus
6	Independent method claim	Treatment of lupus erythematosus, irritable bowel syndrome, premenstrual syndrome, hirsutism, short stature, or sleep disorders
7-9	Dependent	Endometriosis, uterine fibroids, and benign prostatic hypertrophy
10	Dependent on claim 6	Premenstrual syndrome
11-18	Dependent	Infertility, uterine myoma, cancers, polycystic ovarian disease, precocious puberty, and pituitary gonadotroph adenomas

Claims 7 through 18 add little chemical limitation. Their principal effect is to isolate individual indications for enforcement, validity analysis, and possible regulatory listing.

How broad are the chemical claims in US 7,179,815?

The chemical definition is broad at nearly every variable position. The claims permit substantial substitution at R1 through R15, variable linker length, multiple linker heteroatoms, and ring-forming alternatives.

Core chemical breadth

The claim permits:

Direct and linked arrangements through Q.
Linkers containing oxygen, sulfur, nitrogen, sulfoxide, sulfone, sulfonate, amide, urea, carbamate, ester, carbonate, and carbonyl functionality.
A, the scaffold heteroatom, to be O, S, or NR7.
Substituent classes extending from simple alkyl groups to substituted aryl, heteroaryl, and heterocyclic systems.
Cyclic and acyclic alternatives formed by joining substituents.
Salt and stereoisomer forms.
Prodrug forms under claim 6.

This drafting strategy is typical of an early discovery or platform patent. It seeks coverage across a medicinal-chemistry series rather than only the final clinical molecule.

Practical limits on the breadth

The apparent breadth does not automatically translate into enforceable scope. A court would construe the claims against:

The disclosed chemical examples.
The specification’s pharmacological data.
The priority application and any continuation history.
Written-description support for the full Markush genus.
Enablement across the full set of claimed compounds and indications.
The meaning of terms such as “effective amount,” “higher alkyl,” “lower alkyl,” “substituted,” and “condition.”
Any prosecution-history amendments or disclaimers.

The claim text also contains transcription anomalies. Claim 5 includes malformed or inconsistent formula language, including missing punctuation and apparent variable-definition errors. Claim 6 contains typographical errors such as “heterocyclic rind.” Those defects may affect interpretation, but they do not necessarily invalidate the claims if the issued patent and specification provide a clear correction under applicable claim-construction principles.

What therapeutic indications does US 7,179,815 protect?

The patent claims a broad GnRH-related or reproductive-endocrine indication set, although the absent chemical structure prevents definitive target identification from the supplied text alone.

Claimed indications

Therapeutic area	Claimed conditions
Urology	Benign prostatic hypertrophy, prostate cancer
Gynecology	Uterine myoma, uterine fibroids, endometriosis, polycystic ovarian disease, infertility
Oncology	Prostate cancer, uterine cancer, breast cancer
Endocrinology	Pituitary gonadotroph adenomas, precocious puberty, short stature, hirsutism
Reproductive health	Pregnancy prevention
Autoimmune disease	Lupus erythematosus
Gastroenterology	Irritable bowel syndrome
Women’s health	Premenstrual syndrome
Neurology and sleep	Sleep disorders

The overlap between “myoma of the uterus” and “uterine fibroids” creates substantially duplicative indication coverage. Claims 2, 4, 8, and 12 separately reinforce uterine-fibroid-related use.

What is the legal scope of claims 1, 5, and 6?

Claim 1: broad disease-treatment method

Claim 1 requires:

A subject in need of treatment.
Administration of an effective amount.
A compound, stereoisomer, or pharmaceutically acceptable salt falling within the Markush structure.
Treatment of at least one listed condition.

The claim does not specify dose, route, formulation, duration, patient subgroup, biomarker, disease stage, or treatment sequence. Those omissions increase breadth but may create enablement and written-description pressure if the specification lacks data across the full genus and indication list.

Claim 5: pregnancy prevention

Claim 5 is an independent method claim directed to preventing pregnancy. It covers the same broad chemical concept but contains several apparent transcription inconsistencies. Because pregnancy prevention is a distinct clinical objective, infringement would require evidence that the accused product is administered for contraceptive use, not merely that it has reproductive or endocrine activity.

Claim 5 may have commercial significance only if the covered compound is approved, marketed, or clinically developed as a contraceptive. A product approved solely for endometriosis, uterine fibroids, prostate cancer, or another indication would not automatically infringe a pregnancy-prevention method claim.

Claim 6: additional non-reproductive indications and prodrugs

Claim 6 covers treatment of six conditions and expressly includes “prodrug.” It is structurally important because it may reach:

A prodrug not covered by claims 1 or 5.
A metabolically converted version of an active compound.
A formulation or product whose administered form differs from the active species.

The claim’s breadth is counterbalanced by the need to establish that the administered product is a prodrug within the claim and that the use corresponds to one of the specified indications.

When does US Patent 7,179,815 lose exclusivity?

The patent issued on February 20, 2007. A US utility patent generally has a term of 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments. The expiration date therefore depends on the patent’s continuity chain and any term adjustment recorded by the USPTO. [1]

The patent is an old patent by pharmaceutical standards. Its enforceability cannot be assessed from the issue date alone. A current status review should distinguish:

Patent expiration.
Lapse for failure to pay maintenance fees.
Terminal disclaimer.
Patent-term adjustment.
Patent-term extension under 35 U.S.C. § 156.
Reexamination or post-grant certificates.
Continuation, divisional, or continuation-in-part patents.

No Hatch-Waxman exclusivity conclusion follows merely from the existence of US 7,179,815. A later patent family may have replaced or supplemented its commercial protection.

Estimated term relevance

Event	Date or significance
US patent issued	February 20, 2007
Statutory term basis	Generally 20 years from earliest effective nonprovisional filing
Current commercial relevance	Primarily dependent on exact term calculation and related family patents
Patent type	Method-of-use patent based on supplied claims
Regulatory exclusivity	Separate from patent term and must be evaluated through FDA records

The supplied information does not establish a patent-term extension or a current enforceable term. The issue date alone is not a reliable expiration date.

Is US 7,179,815 listed in the FDA Orange Book?

An Orange Book listing is product-specific. FDA lists patents identified by an NDA holder for an approved drug, generally including patents covering the drug substance, drug product, or approved method of use. A broad research patent is not automatically listed. [2]

The supplied claims do not identify:

An approved active ingredient.
An NDA number.
A trade name.
An NDA holder.
A specific dosage form.
A listed indication tied to an approved product.

Accordingly, the patent’s Orange Book significance cannot be inferred from the claims alone. If listed against an approved product, the relevant use claims could support a Paragraph IV challenge or a section viii “skinny label” strategy, depending on the approved indication and the exact listing.

Orange Book implications

Issue	Impact
Compound patent listing	Not established by the supplied claims
Formulation patent listing	Not apparent; claims are method claims
Method-of-use listing	Possible in principle if tied to an approved indication
Paragraph IV exposure	Arises only if an ANDA applicant challenges a listed patent
Section viii carve-out	Potentially relevant for non-protected indications
FDA exclusivity	Separate from patent rights

What Paragraph IV challenges could affect this patent?

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. Under the Hatch-Waxman framework, the NDA holder may sue within 45 days, triggering an automatic stay of FDA approval for up to 30 months, subject to statutory exceptions. [3]

For this patent, likely Paragraph IV theories would include:

Non-infringement

An ANDA applicant could argue that:

Its compound does not satisfy the Markush limitations.
The generic label does not instruct a claimed use.
The product is not a claimed stereoisomer, salt, or prodrug.
The proposed label omits the patented indication.
The method is not practiced by the applicant or its customers in the required manner.

Invalidity

Potential validity attacks include:

Anticipation by an earlier compound or treatment disclosure.
Obviousness based on prior GnRH antagonist or endocrine-modulator chemistry.
Lack of written description for the full Markush genus.
Lack of enablement across the chemical and therapeutic breadth.
Indefiniteness arising from inconsistent variable definitions or unclear structural boundaries.
Unpatentable subject matter concerns are less likely for treatment methods, which are generally patent-eligible when properly claimed.

A broad method claim can be difficult to enforce against a generic if the generic label omits the patented indication. It can be stronger against an originator or specialty product that expressly promotes the claimed use.

Does the patent cover formulation technology?

The supplied claims do not expressly recite:

Tablets.
Capsules.
Injectable depots.
Sustained-release systems.
Nanoparticles.
Specific excipients.
Particle-size distributions.
Solid-state forms.
Polymorphs.
Crystalline salts.
Transdermal or implantable delivery systems.

The patent therefore does not appear, from the supplied claims, to be a formulation patent. It protects administration of the defined compounds for specified conditions.

A later formulation patent could create a separate barrier even after US 7,179,815 expires. Conversely, expiration of this method patent would not eliminate protection under later patents covering dosage form, polymorph, manufacturing process, combination therapy, or a particular clinical regimen.

Does the patent cover manufacturing methods?

No manufacturing step appears in the supplied claims. They do not require:

A particular starting material.
A specified reaction sequence.
A catalyst.
A purification method.
A crystalline form.
A chiral-resolution process.
A specific impurity profile.
A manufacturing site.

Any manufacturing protection would have to arise from separate claims in the patent specification, a related application, or an unrelated family member. The supplied claims alone create no manufacturing or process barrier.

How strong is the patent estate for US 7,179,815?

The patent has strong apparent breadth but uncertain practical strength. Its strongest feature is the combination of a broad chemical genus with multiple high-value therapeutic uses. Its principal vulnerabilities are the scope of the Markush definition, the number of claimed indications, and the absence of dosing or patient-specific limitations.

Strength assessment

Factor	Assessment
Chemical breadth	High on the face of the claims
Indication breadth	High
Formulation protection	Low or absent in supplied claims
Manufacturing protection	Low or absent in supplied claims
Design-around difficulty	Moderate; depends on the missing core structure
Written-description risk	Potentially material for the full genus
Enablement risk	Potentially material across all compounds and indications
Generic-label enforcement	Variable; depends on approved indications
Biosimilar relevance	None for a conventional small-molecule method patent
Commercial durability	Dependent on term and later patent families

The patent’s value is greatest if the covered scaffold is close to a successful, orally active, nonpeptide GnRH antagonist and if the patent’s priority date predates competing clinical programs. Its value is materially lower if marketed products use a different core or if later patents provide the dominant commercial protection.

How does US 7,179,815 compare with patents covering modern GnRH drugs?

The claimed indication set overlaps with current GnRH-pathway products, but overlap in disease use does not establish infringement. Chemical identity is decisive for claims 1, 5, and 6.

Product	Active ingredient	Main US uses	Relevance to US 7,179,815
Orilissa	Elagolix	Endometriosis-associated pain	Requires structural comparison to the omitted formula
Oriahnn	Elagolix combination	Heavy menstrual bleeding associated with uterine fibroids	Same structural question; formulation and combination patents may dominate
Orgovyx	Relugolix	Advanced prostate cancer	Use overlap with claims 1, 3, 13
Myfembree	Relugolix combination	Uterine fibroids and endometriosis	Use overlap with claims 1, 4, 7, and 8
Firmagon	Degarelix	Advanced prostate cancer	Peptide-like antagonist technology and separate product estate
Lupron Depot	Leuprolide acetate	Prostate cancer, endometriosis, fibroids, and other indications	GnRH agonist, not necessarily within this small-molecule genus
Ganirelix products	Ganirelix acetate	Assisted reproduction	Different peptide antagonist class

FDA approval for a listed indication does not establish that the product falls within this patent. A complete freedom-to-operate analysis requires an exact structural comparison and a review of the patent’s prosecution history and family members. [4-8]

Are biosimilars a risk for this patent?

No conventional biosimilar pathway applies to a small-molecule chemical genus. Biosimilars are relevant to biological products licensed under the Public Health Service Act. [9]

For products potentially implicated by these claims, the relevant competitive pathway is generally:

ANDA approval for a therapeutically equivalent small-molecule drug.
Paragraph III certification if the patent has not expired.
Paragraph IV certification if the applicant challenges validity, enforceability, or infringement.
A 505(b)(2) application for a modified active ingredient, prodrug, formulation, or new indication.

A peptide product such as leuprolide or degarelix would raise different regulatory and patent questions from an orally active small-molecule antagonist.

Which companies could challenge or design around this patent?

Potential challengers would include generic manufacturers targeting any approved product whose label overlaps a listed method claim. Large ANDA developers and specialty pharmaceutical companies could pursue:

A non-infringing compound outside the Markush genus.
A label excluding protected indications.
A Paragraph IV challenge.
A 505(b)(2) product with a different salt, formulation, route, or prodrug.
A treatment regimen that avoids a claim limitation, if one exists in the asserted patent or a related patent.

The supplied material identifies no litigation, settlement agreement, license, or covenant not to sue involving US 7,179,815. Those matters cannot be attributed to this patent without a verified litigation and assignment record.

What patent litigation affects US 7,179,815?

The claims supplied do not identify any district-court action, Federal Circuit appeal, inter partes review, ex parte reexamination, or settlement agreement. The patent’s litigation significance should be evaluated through:

USPTO Patent Center.
PACER and district-court dockets.
Federal Circuit opinions.
PTAB proceedings.
FDA Orange Book patent-listing records.
FDA Paragraph IV litigation notices where available.

A patent-number search should distinguish litigation involving the patent itself from litigation involving later patents covering the same active ingredient. The latter may have greater commercial importance even when the earlier patent covers a similar indication.

What licensing deals are associated with US 7,179,815?

The claims alone do not establish a license, assignment, co-development arrangement, or royalty-bearing transaction. Patent ownership and licensing should be separated:

The recorded assignee may not be the current beneficial owner.
A license may be private and absent from the public prosecution file.
A commercial product may rely on a later patent family licensed from a different owner.
A patent family may have been assigned after issuance.

No specific licensing conclusion follows from the claim text.

What generic entry scenarios exist?

Scenario 1: Patent expired or is unenforceable

A generic could launch subject to other unexpired patents, regulatory exclusivity, pediatric exclusivity, and product-specific Orange Book listings. Expiration of US 7,179,815 would remove only this patent as a barrier.

Scenario 2: Product falls outside the Markush genus

A generic or competing innovator could design around the claimed scaffold or a required linker arrangement. This is the most direct chemical design-around route.

Scenario 3: Product falls within the genus but label omits protected uses

A skinny-label strategy could reduce infringement risk if the FDA-approved label excludes the patented indications and the product is not promoted for them.

Scenario 4: Paragraph IV challenge

A challenger could contest written description, enablement, anticipation, obviousness, indefiniteness, or infringement. The commercial outcome would depend heavily on the precise structure and the patent’s prosecution record.

Scenario 5: Later patents remain active

Even if US 7,179,815 no longer blocks launch, later patents may cover:

The specific active ingredient.
A crystalline form or salt.
A dosage regimen.
A combination product.
A sustained-release formulation.
A manufacturing process.
A newly approved indication.

Key Takeaways

US 7,179,815 contains broad method claims directed to a Markush genus of compounds and numerous reproductive, endocrine, oncologic, gynecologic, and other indications.
Claims 1, 5, and 6 are independent method claims; claims 7 through 18 primarily narrow the indication.
The patent does not, from the supplied claims, provide clear formulation or manufacturing protection.
The omitted chemical structure prevents definitive mapping to elagolix, relugolix, degarelix, ganirelix, leuprolide, or another marketed product.
The patent issued on February 20, 2007, but its exact expiration requires the recorded priority chain, patent-term adjustment, terminal-disclaimer, and extension data.
Orange Book relevance is product-specific and cannot be established from the claims alone.
Biosimilar risk is not the relevant pathway for a conventional small-molecule product; ANDA, Paragraph IV, section viii, or 505(b)(2) routes are more relevant.
The primary legal vulnerabilities are written description, enablement, obviousness, indefiniteness, and non-infringement based on chemical structure or label carve-outs.
Later patents covering a specific active ingredient, formulation, regimen, combination, or manufacturing process may be more important to launch timing than this earlier method patent.

FAQs

Could a generic omit the patented indication from its label?

Yes. A section viii carve-out may reduce infringement risk where the patent covers a method of use that is separable from the unprotected uses. FDA and patent-law requirements must both be satisfied.

Does a patent on a GnRH antagonist automatically cover all GnRH antagonists?

No. A Markush claim covers only compounds meeting every structural limitation. Pharmacologic class membership does not establish literal infringement.

Can a prodrug infringe claim 6 even if the parent drug is outside the claim?

Potentially. Claim 6 expressly recites prodrugs, but the accused product must satisfy the claim’s structural and therapeutic limitations.

Does approval for uterine fibroids create infringement under claim 8?

Not by itself. The approved product must also contain or administer a compound within the claimed genus, and the relevant method must be practiced as required by the claim.

What later patents are most likely to delay generic entry?

The highest-risk later patents generally cover the specific active ingredient, crystalline form, formulation, dosage regimen, combination product, or a separately approved indication. Those patents must be reviewed independently from US 7,179,815.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension information. https://www.uspto.gov/patents/laws/patent-term-adjustment
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
U.S. Food and Drug Administration. (2018). Orilissa: Prescribing information.
U.S. Food and Drug Administration. (2020). Orgovyx: Prescribing information.
U.S. Food and Drug Administration. (2021). Myfembree: Prescribing information.
U.S. Food and Drug Administration. (n.d.). Lupron Depot: Prescribing information.
U.S. Food and Drug Administration. (n.d.). Firmagon: Prescribing information.
U.S. Food and Drug Administration. (n.d.). Biosimilars basics. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars-principles-and-provisions

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	548357	⤷ Start Trial
Australia	2004200664	⤷ Start Trial
Australia	3797501	⤷ Start Trial
Australia	767585	⤷ Start Trial
Canada	2398018	⤷ Start Trial
Cyprus	1112815	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,179,815